Personalized mRNA Vaccine Cuts Meloma Recurrence Risk

A personalized mRNA vaccine combined with pembrolizumab reduced melanoma recurrence risk at two years in a large phase 3 trial, new results show.

@sharedot

Personalized mRNA Vaccine Cuts Meloma Recurrence Risk

By @sharedot · · 6 pages

  • Health
  • Melanoma
  • Cancer Vaccines
  • Oncology

A personalized mRNA vaccine combined with pembrolizumab reduced melanoma recurrence risk at two years in a large phase 3 trial, new results show.

A Vaccine Built From Each Patient's Tumor

An experimental personalized cancer vaccine could help keep melanoma from returning after surgery.

The treatment uses mRNA technology to help the immune system recognize and attack cancer cells: each vaccine is tailored to the unique genetic characteristics of an individual patient's tumor to identify tumor-specific targets, strengthening the immune system's ability to find and eliminate cancer cells.

Sutter Health reports that newly released results from the large international phase 3 INTerpath-001 trial show the vaccine combined with pembrolizumab reduced the risk of melanoma recurrence or death at two years compared with pembrolizumab alone.

Georgia Public Broadcasting adds that, according to the drugmakers, patients who received the vaccine were 42% less likely to experience a recurrence within two years than those who did not.

Why This Isn't a Preventive Vaccine

The distinction between this treatment and a conventional vaccine matters.

Dr. Michael Lowe, director of the melanoma program at Emory School of Medicine's Winship Cancer Institute, who led the Atlanta trial, told Georgia Public Broadcasting: "We're not actually trying to prevent cancer on a population basis. We're trying to reduce the risk of melanoma coming back in patients that have had melanoma."

Unlike flu or COVID vaccines, which guard against outside invaders, cancer cells are the body's own mutations gone wild, and every cancer in every person is unique. That means, in theory, every mRNA-based cancer vaccine carries individualized instructions targeting one recipient's tumor biology.

Lowe said the trial asked whether adding the vaccine to pembrolizumab (Keytruda) reduces recurrence risk in patients with surgically removable advanced melanoma.

From Phase 2 Promise to Phase 3 Evidence

The phase 3 findings build on the earlier KEYNOTE-942 study, in which Sutter investigators Dr. Kevin Kim, chief of precision medicine, and Dr. Mohammed Kashani-Sabet, medical director of Sutter CPMC's Cancer Center, led Sutter's participation.

Medical Xpress reports that after five years of follow-up in that phase 2b trial, patients who received the vaccine plus pembrolizumab had a 49% lower risk of recurrence or death and a 59% lower risk of distant spread or death than those on pembrolizumab alone.

The two studies produced different figures because they involved different patient populations and follow-up periods.

"Seeing this research progress from an early clinical trial to promising results in a much larger study is encouraging," Kashani-Sabet said, while Kim called it "precision medicine at its best."

Still Investigational, But Closer to Patients

The personalized vaccine remains investigational and has not been approved by the U.S. Food and Drug Administration, according to Medical Xpress. If approved, it could offer certain patients with high-risk melanoma a new way to reduce the risk of their cancer returning after surgery.

There are practical limits: Emory's Dr. Lowe told Georgia Public Broadcasting that early-stage melanoma patients often don't have sufficient tissue left after surgery to create a vaccine at all, so the current work targets advanced, surgically removable disease.

The trial recently wrapped up in Atlanta, and the broader work involves using synthetic mRNA to spur creation of specific immune-system antibodies so the body itself can help identify and eradicate cancer.

For patients facing the fear of a returning melanoma, a second line of defense after surgery is moving closer to reality.

Sources

  1. medicalxpress.com › Personalized vaccine targets melanoma recurrence
  2. gpb.org › STUDY: Personalized melanoma cancer vaccines can help patients' immune systems attack tumors

More on Health